Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

Double-blind Comparative Randomized Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro Tetravalent Inactivated Split Influenza Vaccine, Solution for Intramuscular Injection, FSUE SPbSRIVS FMBA of Russia, in Volunteers Aged 18-60 Years

The goal of this clinical trial is to assess tolerability, safety and immunogenicity of the Flu-M Quadro vaccine as compared to the Ultrix® Quadri vaccine in volunteers aged between 18 and 60.

Participants were given Flu-M Quadro [inactivated split influenza vaccine] with preservative or Flu-M Quadro [inactivated split influenza vaccine] without preservative or Ultrix® Quadri vaccine.The volunteers of each group were vaccinated with a single dose vaccine.

Researchers assessed the tolerability, safety and immunogenicity of the Flu-M Quadro quadrivalent inactivated split influenza vaccine.

Researchers performed a comparative assessment of the tolerability, safety, and immunogenicity of the Flu-M Quadro quadrivalent inactivated split influenza vaccine and the Ultrix® Quadri vaccine.

Study Overview

• Status: Completed
• Conditions: Vaccine Reaction; Influenza; Influenza, Human; Vaccination; Infection; Influenza Viral Infections
• Intervention / Treatment: Biological: Influenza vaccine [inactivated]

• Study Type: Interventional
• Enrollment (Actual): 450
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Russian Federation
  • Moscow, Russian Federation
    • Bessalar Clinic. Clinical Trial Center Limited Liability Company (Bessalar Clinic. Clinical Trial Center LLC)
  • Perm, Russian Federation
    • Federation (FSBEI of Higher Education "E. A. Wagner PSMU" of the of the Ministry of Health of the Russian Federation)
  • Saint-Petersburg, Russian Federation
    • Baltic Medicine Limited Liability Company (Baltic Medicine LLC)
  • Saint-Petersburg, Russian Federation
    • Eco-Safety Scientific Research and Development Center Limited Liability Company (Eco-Safety Scientific Research and Development Center LLC)
  • Novosibirsk Region
    • Kol'tsovo, Novosibirsk Region, Russian Federation
      • Federally Funded Healthcare Institution Primary Healthcare Unit No. 163,of Federal Medical and Biologic Agency (FFHI PHU No. 163, FMBA of Russia)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy volunteers (men and women) aged 18-60;
• Written informed consent of the volunteers to participate in the clinical trial;
• Volunteers able to fulfill requirements of the protocol (i.e., fill out the patient's diary, come to follow-up visits);
• For fertile women - a negative result of the pregnancy test and consent to observe adequate methods of contraception (usage of contraceptives one month before vaccination and at least two months after vaccination). All females with childbearing potential must have a negative pregnancy test result during the screening period. In the course of the trial women should use barrier contraceptives with a reliability exceeding 90 %, or be sterile, or be in a postmenopausal state. Barrier contraceptives with a reliability exceeding 90 % of common use include cervical caps with spermicide, diaphragms with spermicide, condoms, intra-uterine spirals;
• For the men, are able to conceive - consent to use adequate contraception methods. In the course of the trial and during at least two months after vaccination, men and their sexual partners should use barrier contraceptives with a reliability exceeding 90 %, or be sterile. Barrier contraceptives with a reliability exceeding 90 % of common use include cervical caps with spermicide, diaphragms with spermicide, condoms, intra-uterine spirals;

Exclusion Criteria:

• History of influenza or ARVI or previous influenza vaccination during 9 moths before the trial;
• A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination);
• Allergic reactions to vaccine components or any previous vaccination;
• History of allergic reaction to chicken protein;
• History of Guillain-Barré syndrome (acute polyneuropathy);
• Previous vaccination with rabies vaccines less than 2 months before immunization or scheduled vaccination with rabies vaccines within 1 month after immunization with the trial vaccines;
• Use of any vaccines within 1 month before the vaccination, excluding vaccines according to the National Calendar of Preventive Vaccination, including for epidemic reasons;
• History of leukemia, tuberculosis, cancer, autoimmune diseases;
• Positive blood test results for HIV, syphilis, hepatitis B/C.
• Volunteers who received immunoglobulin or blood products or had a blood transfusion during the last three months before the trial;
• History of long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs for six months before the trial;
• History of any confirmed or suspected immunosuppressive or immunodeficiency condition;
• History of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic or immune systems, mental disease in the acute stage or in the decompensation stage (recovery less than 4 weeks before vaccination);
• History of progressive neurological pathology, convulsive syndrome; Diabetes mellitus, thyrotoxicosis or other diseases of the endocrine system;
• History of eczema;
• Treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (> 10 mg of prednisolone or its equivalent for more than 14 days during the last three months);
• According to the medical history, the volunteer was/is a patient of a tuberculosis dispensary and/or narcological dispensary and/or neuropsychiatric dispensary and/or other;
• History of acute infectious diseases (recovery less than 4 weeks before vaccination);
• Consumption of more than 10 units of alcoholic drinks per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products;
• Smoking of more than 10 cigarettes per day;
• Participation in another clinical trial during the last 3 months;
• Pregnancy or lactation;
• Serious concurrent illnesses or pathological conditions not listed above which, in the opinion of the investigator, could complicate the assessment of the results of the trial including pathological deviations from age norms and laboratory norms of blood and urine parameters, which are clinically significant in the opinion of the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Flu-M Quadro with preservative; 150 volunteers were vaccinated with the Flu-M Quadro Inactivated Split Influenza Vaccine with a preservative	Biological: Influenza vaccine [inactivated]; Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine; Other Names: Ultrix® Quadri
Experimental: Flu-M Quadro without preservative; 150 volunteers were vaccinated with the Flu-M Quadro Inactivated Split Influenza Vaccine without a preservative	Biological: Influenza vaccine [inactivated]; Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine; Other Names: Ultrix® Quadri
Active Comparator: Ultrix® Quadri; 150 volunteers were vaccinated with Ultrix® Quadri Vaccine	Biological: Influenza vaccine [inactivated]; Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine; Other Names: Ultrix® Quadri

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Seroconversion rate for each virus strain (A (H1N1), A (H3N2) and B (Yamagata line and Victoria line)) The percentage of subjects who have a prevaccination titer of influenza haemagglutinin antibody titer (HA titer) ≤ 1:10 and a postvaccination HA titer	Screening (Days 0+5), Day 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of immediate adverse events (allergic reactions)		2 hours after vaccination
Incidence of local adverse events		7 days after vaccination
Incidence of systemic adverse events		7 days after vaccination
Incidence of other adverse reactions		Days 8 to 28 after vaccination
Change from Baseline Geometric mean titer (GMT) ratio of antibodies for each virus strain (A (H1N1), A (H3N2) and B (Yamagata line and Victoria line))	Geometric mean titer (GMT) of antibodies in the blood serums of vaccinated participants in haemagglutination inhibition assay	Screening (Days 0+5), Day 28
Seroconversion factor for each virus strain (A (H1N1), A (H3N2) and B (Yamagata line and Victoria line)) Seroconversion factor is an increase in the geometric mean titers of antibodies at Day 28 vs. the baseline level, expressed in the fold rise		Screening (Days 0+5), Day 28
Seroprotection rate for each virus strain (A (H1N1), A (H3N2) and B (Yamagata line and Victoria line)) Seroprotection rate is the percentage of subjects with a generated protective HA titer (at least 1:40) vs. the baseline level		Screening (Days 0+5), Day 28
Incidence of influenza and ARVI	Incidence, severity, and duration of influenza and ARVI during 6 months after vaccination detected outside of the Protocol.	During 6 months after vaccination
Incidence of severe adverse events		Days 1 to 28 after vaccination
Incidence of withdrawal of a volunteer from the trial due to development of an AE/SAE associated with the use of the trial products		Days 1-7, 14
Number of participants with abnormal physical examination findings	Physical examination of volunteers included an interview, discovery of complaints and symptoms, when required, palpation, auscultation, percussion. During the interview, all complaints and symptoms that had developed since the last visit were identified and assessed. An examination and (when applicable) palpation, auscultation, percussion were performed for the following organs and systems: skin, mucosa, eyes, oral cavity and pharynx, lungs/chest, heart/cardiovascular system, abdominal organs, nervous system, lymph nodes, musculoskeletal system, thyroid gland. The palpation analysis of lymph nodes (submandibular, cervical, ulnar) included an assessment of their size, consistency, pain, mobility, adhesion between themselves and with surrounding tissues and skin	Screening (Days 0+5), Days 1-7, 14, 28
Number of participants with abnormal changes in vital signs - Blood pressure (BP)	BP measurements include the systolic and diastolic blood pressure	Screening (Days 0+5), Days 1-7, 14, 28
Number of participants with abnormal changes in vital signs - Heart rate (HR)	HR is measured using a phonendoscope at the apex of the heart during 1 minute	Screening (Days 0+5), Days 1-7, 14, 28
Number of participants with abnormal changes in vital signs - Respiratory rate (RR)		Screening (Days 0+5), Days 1-7, 14, 28
Number of participants with abnormal changes in vital signs - Body temperature	Body temperature was measured using mercury or digital thermometer, in the armpit for at least 5 minutes	Screening (Days 0+5), Day 1 - before vaccination, 20 minutes and 2, 5-8 hours after vaccination; Days 2-7, 14, 28
Number of participants with clinically significant abnormalities - Complete blood count (CBC)	Red blood cells, Hemoglobin, ESR, Differential Leukocyte Count (segmented and rod neutrophils, lymphocytes, monocytes, eosinophils, basophils), Platelets	Screening (Days 0+5), Days 3, 14, 28
Number of participants with clinically significant abnormalities - Biochemical blood test (BBT)	ALT, AST, Alkaline phosphatase, Total Bilirubin, Total Protein, Urea, Glucose, C-reactive protein, Creatinine, Cholesterol	Screening (Days 0+5), Days 3, 14, 28
Number of participants with clinically significant abnormalities - Urinalysis	pH, Relative Density/Specific Gravity, Protein, Glucose, Red Blood Cells, White Blood Cells	Screening (Days 0+5), Days 3, 14, 28
Number of participants with abnormal changes of total IgE		Screening (Days 0+5), Days 3, 14, 28
Number of participants with abnormal neurological examinations		Screening (Days 0+5), Days 1, 3 (When the interval between the screening visit and visit 1 is more than 3 days), 14, 28
Number of participants with abnormal electrocardiography results	Standard 12-lead ECG	Screening (Days 0+5), Day 3

Collaborators and Investigators

• Sponsor: St. Petersburg Research Institute of Vaccines and Sera
• Investigators: Study Director: Ellina Ruzanova, St. Petersburg Research Institute of Vaccines and Sera

Study record dates

Study Major Dates

• Study Start (Actual): October 6, 2020
• Primary Completion (Actual): December 8, 2020
• Study Completion (Actual): December 8, 2020

Study Registration Dates

• First Submitted: May 11, 2023
• First Submitted That Met QC Criteria: May 11, 2023
• First Posted (Actual): May 22, 2023

Study Record Updates

• Last Update Posted (Actual): May 22, 2023
• Last Update Submitted That Met QC Criteria: May 11, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Influenza; Vaccine; Vaccination; Flu; Inactivated; SPbSRIVS; Quadrivalent; Flu-M Tetra; Split; Flu-M Quadro
• Additional Relevant MeSH Terms: Pathologic Processes; RNA Virus Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Disease Attributes; Orthomyxoviridae Infections; Infections; Communicable Diseases; Virus Diseases; Influenza, Human; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: FMK-II/III-02/20

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No